Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The standard or usual treatment for this disease may be chemotherapy or other types of
treatment to slow the spread of the disease and relieve some symptoms of this cancer.